<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552669</url>
  </required_header>
  <id_info>
    <org_study_id>1-Rodriguez</org_study_id>
    <secondary_id>01-CECI</secondary_id>
    <secondary_id>02-IMA</secondary_id>
    <nct_id>NCT00552669</nct_id>
  </id_info>
  <brief_title>Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents</brief_title>
  <acronym>ORAR III</acronym>
  <official_title>Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro de estudios en Cardiologia Intervencionista</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro de estudios en Cardiologia Intervencionista</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a previous randomized comparison oral sirolimus plus bare metal stent compared to bare
      metal stent implantation alone demonstrated at one year of follow up a significant reduction
      of angiographic and clinical parameters of restenosis (ANMAT resolution number 3366 from June
      2004 and Rodriguez A et al JACC,2006,47,1522-1529). In addition previous reported registries
      from our group with Drug Eluting Stents showed similar amount of reduction in clinical
      parameters (not angiographic)of restenosis (ERACI III, Rodriguez A et al EuroIntervention
      2006,2:53-60). Taking in account that 8.3% of patients treated with oral rapamycin plus Bare
      Metal Stents(ORAR II Trial JACC 2006)and 8.8% of patients treated with DES developed clinical
      restenosis (ERACI III Registry, EuroIntervention 2006) the investigators sought to compare
      differences in overall cost with both revascularization strategies at 1, 2, 3 and 5 years of
      follow up assuming that safety and efficacy clinical end points would be similar.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with de novo lesions treated in different Institutions in Buenos Aires Argentina
      were randomized to treat with oral sirolimus plus bare metal stent implantation (100
      patients) or DES(100 patients).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions.</measure>
    <time_frame>Follow up will be conducted by the coordinating Center at 18 months of follow up</time_frame>
    <description>Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular Events (MACCE)</measure>
    <time_frame>18 Months</time_frame>
    <description>Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>18 months</time_frame>
    <description>Efficacy end point was TVR as revasacularization of the treated vessel.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>A--Oral Rapamycin plus BMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral sirolimus plus bare metal stent implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B -- Drug Eluting Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug Eluting Stents</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral sirolimus</intervention_name>
    <description>Oral sirolimus given orally during 14 days plus bare metal stent implantation was compared with DES.Oral sirolimus was given as bolus of 10 mg started day before intervention followed by 3mg per day during 13 days after PCI. 180 mg of Diltiazem was added during oral administration of sirolimus .</description>
    <arm_group_label>A--Oral Rapamycin plus BMS</arm_group_label>
    <other_name>Oral rapamycine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug Eluting stent</intervention_name>
    <description>Any Drug eluting stent</description>
    <arm_group_label>B -- Drug Eluting Stent</arm_group_label>
    <other_name>DES=Drug Eluting Stents)</other_name>
    <other_name>PES (Paclitaxel Eluting Stent)</other_name>
    <other_name>SES (Sirolimus eluting stent)</other_name>
    <other_name>ZES (Zotarolimus eluting stent)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication of revascularization

          -  De novo lesions

          -  Native vessels

          -  Suitable for stent placement

        Exclusion Criteria:

          -  Acute myocardial infarction within the last 24 hours

          -  In stent restenosis

          -  Previous percutaneous coronary intervention within the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo E Rodriguez, MD PhD FACC</last_name>
    <role>Study Chair</role>
    <affiliation>Departamento de Cardiologia Intervencionista, Sanatorio Otamendi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Fernandez Pereira, MD</last_name>
    <role>Study Director</role>
    <affiliation>Departamento de Cardiologia Intervencionista, Sanatorio Otamendi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica IMA</name>
      <address>
        <city>Adrogue</city>
        <state>Buenos Aires</state>
        <zip>1846</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Las Lomas</name>
      <address>
        <city>San Isidro</city>
        <state>Buenos Aires</state>
        <zip>1354</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Otamendi y Miroli</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1115</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/sites/entrez</url>
    <description>Pubmed abstract of the latest published results.</description>
  </link>
  <reference>
    <citation>Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002 Jun 6;346(23):1773-80.</citation>
    <PMID>12050336</PMID>
  </reference>
  <reference>
    <citation>Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 Oct 2;349(14):1315-23.</citation>
    <PMID>14523139</PMID>
  </reference>
  <reference>
    <citation>Schofer J, Schlüter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G; E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003 Oct 4;362(9390):1093-9.</citation>
    <PMID>14550694</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004 Jan 15;350(3):221-31.</citation>
    <PMID>14724301</PMID>
  </reference>
  <reference>
    <citation>Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME; TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003 Aug 19;108(7):788-94. Epub 2003 Aug 4.</citation>
    <PMID>12900339</PMID>
  </reference>
  <reference>
    <citation>Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004 Feb 17;109(6):701-5. Epub 2004 Jan 26.</citation>
    <PMID>14744976</PMID>
  </reference>
  <reference>
    <citation>Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006 Dec 19;48(12):2584-91. Epub 2006 Nov 2.</citation>
    <PMID>17174201</PMID>
  </reference>
  <reference>
    <citation>Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007 Mar 8;356(10):989-97. Epub 2007 Feb 12.</citation>
    <PMID>17296825</PMID>
  </reference>
  <reference>
    <citation>McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004 Oct 23-29;364(9444):1519-21.</citation>
    <PMID>15500897</PMID>
  </reference>
  <reference>
    <citation>Rodriguez AE, Mieres J, Fernandez-Pereira C, Vigo CF, Rodriguez-Alemparte M, Berrocal D, Grinfeld L, Palacios I. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J Am Coll Cardiol. 2006 Jan 3;47(1):205-7. Epub 2005 Dec 9.</citation>
    <PMID>16386687</PMID>
  </reference>
  <reference>
    <citation>Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007 Feb 24;369(9562):667-78.</citation>
    <PMID>17321312</PMID>
  </reference>
  <reference>
    <citation>Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, Ligthart JM, van Essen D, de Feyter PJ, Serruys PW. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J. 2006 Jan;27(2):166-70. Epub 2005 Oct 25.</citation>
    <PMID>16249221</PMID>
  </reference>
  <reference>
    <citation>Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999 Apr 27;99(16):2164-70.</citation>
    <PMID>10217658</PMID>
  </reference>
  <reference>
    <citation>Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996 Nov 15;98(10):2277-83.</citation>
    <PMID>8941644</PMID>
  </reference>
  <reference>
    <citation>Rodriguez AE, Alemparte MR, Vigo CF, Pereira CF, Llaurado C, Russo M, Virmani R, Ambrose JA. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial). J Invasive Cardiol. 2003 Oct;15(10):581-4.</citation>
    <PMID>14519892</PMID>
  </reference>
  <reference>
    <citation>Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhöfer D, Schühlen H, Goos C, Pache J, Dotzer F, Pogatsa-Murray G, Dirschinger J, Heemann U, Schömig A; OSIRIS Investigators. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation. 2004 Aug 17;110(7):790-5. Epub 2004 Aug 9.</citation>
    <PMID>15302787</PMID>
  </reference>
  <reference>
    <citation>Waksman R, Ajani AE, Pichard AD, Torguson R, Pinnow E, Canos D, Satler LF, Kent KM, Kuchulakanti P, Pappas C, Gambone L, Weissman N, Abbott MC, Lindsay J; Oral Rapamune to Inhibit Restenosis study. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol. 2004 Oct 6;44(7):1386-92.</citation>
    <PMID>15464317</PMID>
  </reference>
  <reference>
    <citation>Rodríguez AE, Rodríguez Alemparte M, Vigo CF, Fernández Pereira C, Llauradó C, Vetcher D, Pocovi A, Ambrose J. Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial). Heart. 2005 Nov;91(11):1433-7. Epub 2005 Mar 17.</citation>
    <PMID>15774608</PMID>
  </reference>
  <reference>
    <citation>Rodriguez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF, Delgado J, Fernandez-Pereira C, Pocovi A, Rodriguez-Granillo AM, Schulz D, Raizner AE, Palacios I, O'Neill W, Kaluza GL, Stone G; ORAR II Investigators. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol. 2006 Apr 18;47(8):1522-9. Epub 2006 Mar 29.</citation>
    <PMID>16630986</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME; TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005 Sep 14;294(10):1215-23.</citation>
    <PMID>16160130</PMID>
  </reference>
  <reference>
    <citation>Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, Williams DO. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007 May 9;297(18):1992-2000.</citation>
    <PMID>17488964</PMID>
  </reference>
  <reference>
    <citation>Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, Kleiman NS; EVENT Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007 May 9;297(18):2001-9.</citation>
    <PMID>17488965</PMID>
  </reference>
  <reference>
    <citation>Rodriguez AE, Maree AO, Mieres J, Berrocal D, Grinfeld L, Fernandez-Pereira C, Curotto V, Rodriguez-Granillo A, O'Neill W, Palacios IF. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. Eur Heart J. 2007 Sep;28(17):2118-25. Epub 2007 Jul 25.</citation>
    <PMID>17656352</PMID>
  </reference>
  <reference>
    <citation>Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.</citation>
    <PMID>17470709</PMID>
  </reference>
  <reference>
    <citation>Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP; REALITY Trial Investigators. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA. 2006 Feb 22;295(8):895-904.</citation>
    <PMID>16493102</PMID>
  </reference>
  <reference>
    <citation>Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE; ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006 Dec 19;48(12):2440-7. Epub 2006 Nov 28.</citation>
    <PMID>17174180</PMID>
  </reference>
  <reference>
    <citation>Agostoni P, Valgimigli M, Abbate A, Cosgrave J, Pilati M, Biondi-Zoccai GG. Is late luminal loss an accurate predictor of the clinical effectiveness of drug-eluting stents in the coronary arteries? Am J Cardiol. 2006 Mar 1;97(5):603-5. Epub 2006 Jan 6.</citation>
    <PMID>16490421</PMID>
  </reference>
  <reference>
    <citation>Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006 Jul 4;48(1):193-202. Epub 2006 May 5.</citation>
    <PMID>16814667</PMID>
  </reference>
  <reference>
    <citation>Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol. 2005 Jul 19;46(2):231-6.</citation>
    <PMID>16022947</PMID>
  </reference>
  <reference>
    <citation>Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, Mintz GS, Nagata S. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006 May 16;47(10):2108-11. Epub 2006 Apr 4. Review.</citation>
    <PMID>16697331</PMID>
  </reference>
  <reference>
    <citation>Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006 Jun 20;113(24):2803-9. Epub 2006 Jun 12.</citation>
    <PMID>16769908</PMID>
  </reference>
  <reference>
    <citation>Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007 Jun 19;49(24):2312-7. Epub 2007 Jun 4.</citation>
    <PMID>17572245</PMID>
  </reference>
  <reference>
    <citation>Ho PM, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC, Jesse RA, Rumsfeld JS. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008 Feb 6;299(5):532-9. doi: 10.1001/jama.299.5.532. Erratum in: JAMA. 2008 May 28;299(20):2390.</citation>
    <PMID>18252883</PMID>
  </reference>
  <reference>
    <citation>Brunner-La Rocca HP, Kaiser C, Bernheim A, Zellweger MJ, Jeger R, Buser PT, Osswald S, Pfisterer M; BASKET Investigators. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis. Lancet. 2007 Nov 3;370(9598):1552-9.</citation>
    <PMID>17980734</PMID>
  </reference>
  <reference>
    <citation>Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, Leon MB, Moses JW, Carrozza JP Jr, Zidar JP, Kuntz RE; SIRIUS Investigators. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation. 2004 Aug 3;110(5):508-14. Epub 2004 Jul 19.</citation>
    <PMID>15262844</PMID>
  </reference>
  <reference>
    <citation>Bakhai A, Stone GW, Mahoney E, Lavelle TA, Shi C, Berezin RH, Lahue BJ, Clark MA, Lacey MJ, Russell ME, Ellis SG, Hermiller JB, Cox DA, Cohen DJ; TAXUS-IV Investigators. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol. 2006 Jul 18;48(2):253-61. Epub 2006 Jun 22.</citation>
    <PMID>16843171</PMID>
  </reference>
  <reference>
    <citation>Hausleiter J, Kastrati A. Is there a role for oral rapamycin in restenosis prevention after bare-metal stent implantation? Nat Clin Pract Cardiovasc Med. 2006 Sep;3(9):476-7.</citation>
    <PMID>16932762</PMID>
  </reference>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2007</study_first_submitted>
  <study_first_submitted_qc>November 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2007</study_first_posted>
  <results_first_submitted>March 31, 2009</results_first_submitted>
  <results_first_submitted_qc>July 10, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2009</results_first_posted>
  <last_update_submitted>May 27, 2010</last_update_submitted>
  <last_update_submitted_qc>May 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alfredo E Rodriguez, MD, PHD, FACC, FSCAI</name_title>
    <organization>Centro de Estudios en Cardiologia Intervencionista</organization>
  </responsible_party>
  <keyword>Drug Eluting Stents</keyword>
  <keyword>Stents Bare Metal</keyword>
  <keyword>Stent Thrombosis</keyword>
  <keyword>Coronary revascularization</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between January 2006 to September 2007 we enrolled 200 patients in the trial.</recruitment_details>
      <pre_assignment_details>From 1274 patients with coronary angiography, 789 met clinical inclusion criteria, from whom 102 have angiographic exclusion criteria. 487 were excluded for inability for percutaneous coronary intervention (PCI) with drug eluting stent (DES) deployment or refuse to participate in the study; thus 200 patients were included in this randomized trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Sirolimus + Bare Metal Stent</title>
          <description>Oral sirolimus plus bare metal stent implantation</description>
        </group>
        <group group_id="P2">
          <title>Drug Eluting Stents</title>
          <description>Any Drug Eluting Stents</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100">patients</participants>
                <participants group_id="P2" count="100">patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97">All patients were followed for 18.3 +/- 7 months.</participants>
                <participants group_id="P2" count="93">All patients were followed for 18.3 +/- 7 months.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Sirolimus + Bare Metal Stent</title>
          <description>Oral sirolimus plus bare metal stent implantation</description>
        </group>
        <group group_id="B2">
          <title>Drug Eluting Stents</title>
          <description>Any Drug Eluting Stents</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="10.1"/>
                    <measurement group_id="B2" value="63.4" spread="10.6"/>
                    <measurement group_id="B3" value="63.2" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions.</title>
        <description>Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions.</description>
        <time_frame>Follow up will be conducted by the coordinating Center at 18 months of follow up</time_frame>
        <population>All patients were analyzed for ITT and the imputation technique was LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Sirolimus + Bare Metal Stent</title>
            <description>Oral sirolimus plus bare metal stent implantation</description>
          </group>
          <group group_id="O2">
            <title>Drug Eluting Stents</title>
            <description>Any Drug Eluting Stents</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions.</title>
          <description>Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions.</description>
          <population>All patients were analyzed for ITT and the imputation technique was LOCF</population>
          <units>US dollars</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5483" spread="2165.5"/>
                    <measurement group_id="O2" value="7658.2" spread="3263.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We used One way annalysis of a variance for means and standard deviation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiovascular Events (MACCE)</title>
        <description>Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke.</description>
        <time_frame>18 Months</time_frame>
        <population>It was determinated by ITT and the technique used was LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Sirolimus + Bare Metal Stent</title>
            <description>Oral sirolimus plus bare metal stent implantation</description>
          </group>
          <group group_id="O2">
            <title>Drug Eluting Stents</title>
            <description>Any Drug Eluting Stents</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiovascular Events (MACCE)</title>
          <description>Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke.</description>
          <population>It was determinated by ITT and the technique used was LOCF.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MACCE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on our previous data the incidence of relevant clinical events was similar in both groups (ERACI III and ORAR II)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR)</title>
        <description>Efficacy end point was TVR as revasacularization of the treated vessel.</description>
        <time_frame>18 months</time_frame>
        <population>We analyzed the number of vessels treated per group by ITT and the imputation technique was LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Sirolimus + Bare Metal Stent</title>
            <description>Oral sirolimus plus bare metal stent implantation</description>
          </group>
          <group group_id="O2">
            <title>Drug Eluting Stents</title>
            <description>Any Drug Eluting Stents</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR)</title>
          <description>Efficacy end point was TVR as revasacularization of the treated vessel.</description>
          <population>We analyzed the number of vessels treated per group by ITT and the imputation technique was LOCF.</population>
          <units>vessels</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>power calculation 80% Hypothesis: No significant diferences between Target Vessel Revascularization (TVR) between both groups.
All events will be recorded and an independent blind for groups clinical events committee will adjudicate each one.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Sirolimus + Bare Metal Stent</title>
          <description>Oral sirolimus plus bare metal stent implantation</description>
        </group>
        <group group_id="E2">
          <title>Drug Eluting Stents</title>
          <description>Any Drug Eluting Stents</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9"/>
                <counts group_id="E2" subjects_affected="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cardiac Death</sub_title>
                <counts group_id="E1" events="9" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="15" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Non Cardiac Death</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="15" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="9" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="15" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>None hospitalization was needed for any participant patient</description>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <description>None hospitalization was needed for any participant patient</description>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>It was an open label design. Multiple approved DES designs were used. Health Care system in Argentina differs from other world ones.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alfredo Rodriguez, MD, PHD</name_or_title>
      <organization>Centro de Estudios en Cardiologia Intervencionista</organization>
      <phone>541149648721</phone>
      <email>rodrigueza@sanatorio-otamendi.com.ar</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

